1 SENATE FLOOR VERSION
April 23, 2025
2 AS AMENDED
3 ENGROSSED HOUSE
BILL NO. 1808 By: Newton, Deck, Pae, Miller,
4 Munson, Dempsey, and Lawson
of the House
5
and
6
Rader and Stanley of the
7 Senate
8
9
10 [ health insurance - Ensuring Transparency in
Prescription Drugs Prior Authorization Act -
11 disclosure and review of prior authorization for
prescription drugs - adverse determinations -
12 consultation - reviewing physicians - exception -
retrospective denial - continuity of care -
13 transmission of authorization – noncodification –
codification - effective date ]
14
15
16
17 BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
18 SECTION 1. NEW LAW A new section of law not to be
19 codified in the Oklahoma Statutes reads as follows:
20 This act shall be known and may be cited as the "Ensuring
21 Transparency in Prescription Drugs Prior Authorization Act".
22 SECTION 2. NEW LAW A new section of law to be codified
23 in the Oklahoma Statutes as Section 6570.50 of Title 36, unless
24 there is created a duplication in numbering, reads as follows:
SENATE FLOOR VERSION - HB1808 SFLR Page 1
(Bold face denotes Committee Amendments)

1 As used in this act:
2 1. "Adverse determination" means a determination by a health
3 carrier, pharmacy benefits manager (PBM), or its designee
4 utilization review entity that a prescription drug that is a covered
5 benefit has been reviewed and, based upon the information provided,
6 does not meet the health plan's or PBM's requirements for medical
7 necessity, appropriateness, health care setting, level of care, or
8 effectiveness, and the requested prescription drug or payment for
9 the prescription drug is therefore denied, reduced, or terminated as
10 defined by Section 6475.3 of Title 36 of the Oklahoma Statutes;
11 2. "Chronic condition" means a condition that lasts one (1)
12 year or more and requires ongoing medical attention or limits
13 activities of daily living or both;
14 3. "Clinical criteria" means the written policies, written
15 screening procedures, determination rules, determination abstracts,
16 clinical protocols, practice guidelines, medical protocols, and any
17 other criteria or rationale used by the utilization review entity to
18 determine the necessity and appropriateness of prescription drugs;
19 4. "Emergency health care services", with respect to an
20 emergency medical condition as defined in 42 U.S.C.A., Section
21 300gg-111, means:
22 a. a medical screening examination, as required under
23 Section 1867 of the Social Security Act, 42 U.S.C.,
24 Section 1395dd, or as would be required under such
SENATE FLOOR VERSION - HB1808 SFLR Page 2
(Bold face denotes Committee Amendments)

1 section if such section applied to an independent,
2 freestanding emergency department, that is within the
3 capability of the emergency department of a hospital
4 or of an independent, freestanding emergency
5 department, as applicable, including ancillary
6 services routinely available to the emergency
7 department to evaluate such emergency medical
8 condition, and
9 b. within the capabilities of the staff and facilities
10 available at the hospital or the independent,
11 freestanding emergency department, as applicable, such
12 further medical examination and treatment as are
13 required under Section 1395dd of the Social Security
14 Act, or as would be required under such section if
15 such section applied to an independent, freestanding
16 emergency department, to stabilize the patient,
17 regardless of the department of the hospital in which
18 such further examination or treatment is furnished, as
19 defined by 42 U.S.C.A., Section 300gg-111;
20 5. "Emergency Medical Treatment and Active Labor Act" or
21 "EMTALA" means Section 1867 of the Social Security Act and
22 associated regulations;
23
24
SENATE FLOOR VERSION - HB1808 SFLR Page 3
(Bold face denotes Committee Amendments)

1 6. "Enrollee" means an individual who is enrolled in a health
2 care plan, including covered dependents, as defined by Section
3 6592.1 of Title 36 of the Oklahoma Statutes;
4 7. "Health care provider" means any person or other entity who
5 is licensed pursuant to the provisions of Title 59 or Title 63 of
6 the Oklahoma Statutes, or pursuant to the definition in Section 1-
7 1708.1C of Title 63 of the Oklahoma Statutes;
8 8. "Health plan" means a health benefit plan as defined by
9 Section 6060.4 of Title 36 of the Oklahoma Statutes;
10 9. "Licensed mental health professional" means:
11 a. a psychiatrist who is a diplomate of the American
12 Board of Psychiatry and Neurology,
13 b. a psychiatrist who is a diplomate of the American
14 Osteopathic Board of Neurology and Psychiatry, or
15 c. a physician licensed pursuant to the Oklahoma
16 Allopathic Medical and Surgical Licensure and
17 Supervision Act or the Oklahoma Osteopathic Medicine
18 Act;
19 10. "Medically necessary" means drugs prescribed by a health
20 care provider that are:
21 a. appropriate for the symptoms and diagnosis or
22 treatment of the enrollee's condition, illness,
23 disease, or injury,
24 b. in accordance with standards of good medical practice,
SENATE FLOOR VERSION - HB1808 SFLR Page 4
(Bold face denotes Committee Amendments)

1 c. not primarily for the convenience of the enrollee or
2 the enrollee's health care provider, and
3 d. the most appropriate supply and prescription drug that
4 can safely be provided to the enrollee as defined by
5 Section 6592 of Title 36 of the Oklahoma Statutes;
6 11. "Notice" means communication delivered either
7 electronically or through the United States Postal Service or common
8 carrier;
9 12. "Pharmacist" means a person licensed by the Board of
10 Pharmacy to engage in the practice of pharmacy;
11 13. "PBM" means a pharmacy benefits manager as defined by
12 Section 357 of Title 59 of the Oklahoma Statutes;
13 14. "Physician" means an allopathic or osteopathic physician
14 licensed by the State of Oklahoma or another state to practice
15 medicine;
16 15. "Prior authorization" means the process by which
17 utilization review entities determine the medical necessity and
18 medical appropriateness of otherwise covered prescription drug prior
19 to the dispensing of such prescription drug. The term shall include
20 "authorization", "pre-certification", and any other term that would
21 be a reliable determination by a health benefit plan;
22 16. "Urgent prescription drug" means a prescription drug with
23 respect to which the application of the time periods for making an
24
SENATE FLOOR VERSION - HB1808 SFLR Page 5
(Bold face denotes Committee Amendments)

1 urge nt care determination, which, in the opinion of a physician with
2 knowledge of the enrollee's medical condition:
3 a. could seriously jeopardize the life or health of the
4 enrollee or the ability of the enrollee to regain
5 maximum function, or
6 b. in the opinion of a physician with knowledge of the
7 claimant's medical condition, would subject the
8 enrollee to severe pain that cannot be adequately
9 managed without the care or treatment that is the
10 subject of the utilization review; and
11 17. "Utilization review entity" means an individual or entity
12 that performs prior authorization for a health benefit plan as
13 defined by Section 6060.4 of Title 36 of the Oklahoma Statutes.
14 SECTION 3. NEW LAW A new section of law to be codified
15 in the Oklahoma Statutes as Section 6570.51 of Title 36, unless
16 there is created a duplication in numbering, reads as follows:
17 A utilization review entity shall make any current prescription
18 drug prior authorization requirements and restrictions, including
19 written clinical criteria, readily accessible on its website to
20 enrollees and health care providers. Prior authorization
21 requirements shall be described in detail but also in easily
22 understandable language.
23
24
SENATE FLOOR VERSION - HB1808 SFLR Page 6
(Bold face denotes Committee Amendments)

1 Any health plan shall make any current prescription drug plan
2 formulary readily accessible on its website to enrollees and health
3 care providers.
4 All health benefit plans shall submit a secured webpage link for
5 the plan's formulary, to the Insurance Commissioner, on or before
6 October 1 of each year. The Commissioner shall issue guidance and
7 standardized reporting requirements to ensure compliance with the
8 provisions of this section. Any confidential or trade secret
9 information shall be redacted prior to submission to the
10 Commissioner. No later than December 31, 2025, and by December 31
11 of each year thereafter, the Commissioner shall make available to
12 the public the reports submitted by insurers, as required by this
13 section.
14 If a utilization review entity intends either to implement a new
15 prior authorization requirement or restriction, or amend an existing
16 requirement or restriction, the utilization review entity shall
17 ensure that the new or amended requirement or restriction is not
18 implemented unless the utilization review entity's website has been
19 updated to reflect the new or amended requirement or restriction.
20 If a utilization review entity intends either to implement a new
21 prior authorization requirement or restriction, or amend an existing
22 requirement or restriction, the utilization review entity shall
23 provide contracted health care providers credentialed to prescribe
24 the drug, or enrollees who have a chronic condition and are already
SENATE FLOOR VERSION - HB1808 SFLR Page 7
(Bold face denotes Committee Amendments)

1 rece iving the prescription drug which the prior authorization
2 changes will impact, notice of the new or amended requirement or
3 restriction no less than sixty (60) days before the requirement or
4 restriction is implemented.
5 Provided the provisions of this section do not violate any
6 applicable law, regulation, or the Oklahoma Medicaid State Plan.
7 SECTION 4. NEW LAW A new section of law to be codified
8 in the Oklahoma Statutes as Section 6570.52 of Title 36, unless
9 there is created a duplication in numbering, reads as follows:
10 A utilization review entity shall ensure that all adverse
11 determinations include alternative prescription drugs covered by the
12 health plan's formulary and are made by a physician, pharmacist, or
13 licensed mental health professional. The physician, pharmacist, or
14 licensed mental health professional shall:
15 1. Possess a current and valid nonrestricted license in any
16 United States jurisdiction;
17 2. Have the appropriate training, knowledge, or expertise to
18 apply appropriate clinical guidelines to the health care service
19 being requested; and
20 3. Make the adverse determination under the clinical direction
21 provided by the committee or board responsible for developing
22 policies for drug use, evaluating clinical appropriateness, and
23 ensuring effective drug use when reviewing prescription drug prior
24
SENATE FLOOR VERSION - HB1808 SFLR Page 8
(Bold face denotes Committee Amendments)

1 auth orizations to enrollees of Oklahoma. All such medical directors
2 shall be physicians licensed in any United States jurisdiction.
3 SECTION 5. NEW LAW A new section of law to be codified
4 in the Oklahoma Statutes as Section 6570.53 of Title 36, unless
5 there is created a duplication in numbering, reads as follows:
6 A utilization review entity shall ensure that all appeals are
7 reviewed by a physician, pharmacist, or licensed mental health
8 professional. The physician, pharmacist, or licensed mental health
9 professional shall:
10 1. Possess a current and valid unrestricted license in any
11 United States jurisdiction;
12 2. Be of the same or similar specialty as a physician,
13 pharmacist, or licensed mental health professional who typically
14 manages the medical condition or disease, which means that the
15 physician either maintains board certification for the same or
16 similar specialty as the medical condition in question or whose
17 training and experience:
18 a. includes treating the condition,
19 b. includes treating complications that may result from
20 the service or procedure, and
21 c. is sufficient for the physician, pharmacist, or
22 licensed mental health professional to determine if
23 the service or procedure is medically necessary or
24 clinically appropriate,
SENATE FLOOR VERSION - HB1808 SFLR Page 9
(Bold face denotes Committee Amendments)

1 exce pt for appeals coming from a licensed mental health
2 professional, which may be conducted by another licensed mental
3 health professional as opposed to a physician, or for appeals coming
4 from a pharmacist, which may be conducted by another licensed
5 pharmacist as opposed to a physician;
6 3. Not have been directly involved in making the adverse
7 determination;
8 4. Not have any financial interest in the outcome of the
9 appeal; and
10 5. Consider all known clinical aspects of the health care
11 service under review, including, but not limited to, a review of
12 those medical records which are pertinent and relevant to the active
13 condition provided to the utilization review entity by the
14 enrollee's health care provider, or a health care facility, and any
15 pertinent medical literature provided to the utilization review
16 entity by the health care provider.
17 SECTION 6. NEW LAW A new section of law to be codified
18 in the Oklahoma Statutes as Section 6570.54 of Title 36, unless
19 there is created a duplication in numbering, reads as follows:
20 A. If a utilization review entity requires prior authorization
21 of a prescription drug, the utilization review entity shall make a
22 prior authorization or adverse determination and notify the enrollee
23 and the enrollee's health care provider of the prior authorization
24
SENATE FLOOR VERSION - HB1808 SFLR Page 10
(Bold face denotes Committee Amendments)

1 or a dverse determination in accordance with the time frames set
2 forth below:
3 1. For purposes of approving prior authorization for urgent
4 prescription drugs, within twenty-four (24) hours of obtaining all
5 necessary information to make the prior authorization or adverse
6 determination; or
7 2. For purposes of approving prior authorization for nonurgent
8 prescription drugs, within four (4) business days of obtaining all
9 necessary information to make the prior authorization or adverse
10 determination.
11 For purposes of this section, "necessary information" includes,
12 but is not limited to, the results of any face-to-face clinical
13 evaluation or second opinion that may be required.
14 B. For those health care providers that submit all necessary
15 information through the utilization review entity's authorized prior
16 authorization system, prescription drugs are deemed authorized if a
17 utilization review entity fails to comply with the deadlines set
18 forth in this section.
19 C. In the notification to the health care provider that a prior
20 authorization has been approved, the utilization review entity shall
21 include in such notification the duration of the prior authorization
22 or the date by which the prior authorization will expire.
23
24
SENATE FLOOR VERSION - HB1808 SFLR Page 11
(Bold face denotes Committee Amendments)

1 SECTION 7. NEW LAW A new section of law to be codified
2 in the Oklahoma Statutes as Section 6570.55 of Title 36, unless
3 there is created a duplication in numbering, reads as follows:
4 A utilization review entity shall not require prior
5 authorization for prescription drugs administered as a part of the
6 provision of emergency health care services.
7 SECTION 8. NEW LAW A new section of law to be codified
8 in the Oklahoma Statutes as Section 6570.56 of Title 36, unless
9 there is created a duplication in numbering, reads as follows:
10 A. If a prior authorization is required for a prescription drug
11 for the treatment of a chronic condition of an enrollee, and the
12 enrollee remains on the same health plan, then the prior
13 authorization shall remain valid for three (3) years from the date
14 the health care provider receives the prior authorization approval,
15 unless clinical criteria changes, the enrollee's health plan removes
16 the generic prescription drug from the formulary, or moves the
17 prescription drug to a less preferred tier status on its formulary.
18 B. This section shall not apply to prior authorizations
19 approved for:
20 1. A prescription drug that is an opioid or is a controlled
21 substance that is prohibited from being dispensed without a
22 prescription under the Federal Food, Drug, and Cosmetic Act, 21
23 U.S.C., Section 301 et seq., as amended; or
24 2. A prescription drug for the treatment of weight loss.
SENATE FLOOR VERSION - HB1808 SFLR Page 12
(Bold face denotes Committee Amendments)

1 C. Provided the provisions of this section do not violate any
2 applicable law, regulation, or the Oklahoma Medicaid State Plan.
3 SECTION 9. NEW LAW A new section of law to be codified
4 in the Oklahoma Statutes as Section 6570.57 of Title 36, unless
5 there is created a duplication in numbering, reads as follows:
6 A. On receipt of information documenting a prior authorization
7 from the enrollee or from the enrollee's health care provider, a
8 utilization review entity shall honor a prior authorization granted
9 to an enrollee from a previous utilization review entity for at
10 least the initial sixty (60) days of an enrollee's coverage under a
11 new health plan.
12 B. During the time period described in subsection A of this
13 section, a utilization review entity may perform its own review to
14 grant a prior authorization or make an adverse determination.
15 C. A utilization review entity shall continue to honor a prior
16 authorization it has granted to an enrollee when the enrollee
17 changes products under the same health insurance company for the
18 initial sixty (60) days of an enrollee's coverage under the new
19 product unless the service is no longer a covered service under the
20 new product.
21 D. During the time period described in subsection C of this
22 section, a utilization review entity may simultaneously perform a
23 review to grant a prior authorization or to make an adverse
24 determination.
SENATE FLOOR VERSION - HB1808 SFLR Page 13
(Bold face denotes Committee Amendments)

1 E. Provided the provisions of this section do not violate any
2 applicable law, regulation, or the Oklahoma Medicaid State Plan.
3 SECTION 10. NEW LAW A new section of law to be codified
4 in the Oklahoma Statutes as Section 6570.58 of Title 36, unless
5 there is created a duplication in numbering, reads as follows:
6 A. 1. The Insurance Commissioner may, if the Commissioner
7 finds that any person or organization has violated the provisions of
8 this act, impose a penalty of not more than Five Thousand Dollars
9 ($5,000.00) for each such violation. Such penalties may be in
10 addition to any other penalty provided by law.
11 2. No penalty shall be imposed except upon written order of the
12 Commissioner or the appointed independent hearing examiner, stating
13 the findings of the Commissioner or the appointed independent
14 hearing examiner after the notice and opportunity for a hearing in
15 accordance with Article II of the Administrative Procedures Act.
16 B. 1. The Attorney General may, if the Attorney General finds
17 that a pharmacy benefits manager has violated the provisions of this
18 act, impose a penalty of not more than Five Thousand Dollars
19 ($5,000.00) for each such violation. Such penalties may be in
20 addition to any other penalty provided by law.
21 2. No penalty shall be imposed except upon written order of the
22 Attorney General or the appointed independent hearing examiner,
23 stating the findings of the Attorney General or the appointed
24 independent hearing examiner after the notice and opportunity for a
SENATE FLOOR VERSION - HB1808 SFLR Page 14
(Bold face denotes Committee Amendments)

1 hear ing in accordance with Article II of the Administrative
2 Procedures Act.
3 SECTION 11. NEW LAW A new section of law to be codified
4 in the Oklahoma Statutes as Section 6570.59 of Title 36, unless
5 there is created a duplication in numbering, reads as follows:
6 This act shall apply to the Oklahoma Medicaid State Plan.
7 SECTION 12. This act shall become effective November 1, 2025.
8 COMMITTEE REPORT BY: COMMITTEE ON APPROPRIATIONS
April 23, 2025 - DO PASS AS AMENDED
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
SENATE FLOOR VERSION - HB1808 SFLR Page 15
(Bold face denotes Committee Amendments)

[DELETED: P B N  a R]
[DELETED: P a]
[DELETED: P w]
[DELETED: P a a a a i]
[DELETED: P n t]
[DELETED: P c i]
[DELETED: P]
[DELETED: P]
[DELETED: P i i i]
[DELETED: P]
[DELETED: P]
[DELETED: P]
[DELETED: P]
[DELETED: P]
[DELETED: P]